News & Updates
Filter by Specialty:
Show Multimedia Only
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
byAudrey Abella
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Enzalutamide-ADT a win for biochemically recurrent prostate cancer
27 Oct 2025
byAudrey Abella
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.
